EUVIMEDEUVIMED entdecken
Übersichtsarbeit

ZBTB7A as a therapeutic target for cancer

Ying Zhou, Xisha Chen, Xuyu Zu

Biochemical and Biophysical Research Communications · 2024

DOI: 10.1016/j.bbrc.2024.150888 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Ying Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Hauptthemen laut MEDLINE: Neoplasms, Transcription Factors, DNA-Binding Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ZBTB7A, alternatively referred to Pokemon, FBI-1, LRF, and OCZF, is classified as a member of POK/ZBTB protein family of transcriptional repressors. ZBTB7A binds to targeted DNA via C-terminal zinc fingers and recruits co-compression complexes through N-terminal BTB ⁄ POZ domain to impede transcription. ZBTB7A regulates a range of fundamental biological processes such as cell proliferation, differentiation and apoptosis, B- and T-lymphocyte fate determination and thymic insulin expression and self-tolerance. Accumulating evidence has demonstrated an important role of ZBTB7A in the initiation and advancement of tumors, thus making ZBTB7A emerge as an appealing target. This review examines the functions and regulatory mechanisms of ZBTB7A in a range of common solid tumors, including hepatocellular carcinoma, breast cancer, prostate cancer and lung cancer, as well as hematological malignancies. Notably, the review concludes with a summary of the recent applications of targeting ZBTB7A in clinical treatments through gene silencing, immunotherapy and chemotherapeutic approaches to halt or slow tumor progression. We focus on the functional role and regulatory mechanisms of ZBTB7A in cancer with the goal of providing new insights for the development of more effective cancer therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTranscription FactorsDNA-Binding ProteinsHumansAnimalsMolecular Targeted TherapyGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CancerCancer therapeutic strategiesRegulatory mechanismTargetZBTB7A

Substanzen

ZBTB7A protein, humanTranscription FactorsDNA-Binding Proteins

Autor:innen und Institutionen

  • Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
  • Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. Electronic address: chen_xisha@foxmail.com.
  • Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China; Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Majo…

Förderung

  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Zhou, Y., Chen, X., & Zu, X. (2024). ZBTB7A as a therapeutic target for cancer. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150888

Vancouver

Zhou Y, Chen X, Zu X. ZBTB7A as a therapeutic target for cancer. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150888

BibTeX
@article{Zhou2024,
  author = {Zhou, Ying and Chen, Xisha and Zu, Xuyu},
  title = {ZBTB7A as a therapeutic target for cancer},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  doi = {10.1016/j.bbrc.2024.150888}
}
Kostenlos starten →